Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Glossary Glossary
The Body Covers: The XIII International AIDS Conference
Abacavir, Lamivudine, and Efavirenz

July 12, 2000

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

  • Use of efavirenz in a low-income population (Poster, WePeB4138)
    Authored by D. Parrish, J. Godbey
  • Evaluation of novel combination of abacavir (ABC), lamivudine (3TC) and efavirenz (EFV) (Poster, WePeB4139)
    Authored by J. Godbey, D. Parrish


As several studies have shown the effectiveness of Sustiva (efavirenz), there has been an emphasis in helping us understand who can and cannot tolerate this medication. This is particularly true given the potential for changes in mood and sleep patterns in the first few days to weeks of its use. Therefore, this study was done to report on the safety of using efavirenz in those with a history of either a mental health diagnosis such as depression, or a history of substance use, or both.

The researchers gave 21 patients a regimen containing efavirenz, and used a unique approach of initially giving d4T, 3TC, and efavirenz for one month, and then substituting abacavir instead of the d4T. This was done to avoid overlapping the start dates of both efavirenz and abacavir. There are potentially overlapping side effects (especially a rash), and it was considered easier to separate starting these drugs so as to make it clearer which drug was likely causing the rash if it happened. Overall, about 71% had a history of some mental health condition, while 43% had both a history of mental health disorders and a history of substance use. They reported only one discontinuation due to intolerance (fatigue), despite the occurrence of the typical Sustiva side effects noted in the first month, such as vivid dreams or dizziness. While two people did have worsening mood which led them to substitute nevirapine for efavirenz in this study, the patients did not demonstrate improvement on the new regimen. This was thought to suggest that efavirenz was unlikely to be the cause of the mental health condition but rather the mental health problem itself was worse at that time.

In terms of the viral load response, it is noted that while all patients were non-nucleoside-naive, some had pretreatment with other antivirals, including 3TC, one of the medications in this combination. Despite this, they reported that out of 17 patients, 53% achieved a viral load below 50 copies, and 82% had a viral load below 400 copies.

The researchers reported that the extensive counseling that they did before treating their patients may have been of help in maintaining their patients on this otherwise simple regimen. This message can be of use in considering treatment options, even for those with significant other medical concerns.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

See Also
More Research on HIV/AIDS Treatment Strategies
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement